JP2019511529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511529A5 JP2019511529A5 JP2018553368A JP2018553368A JP2019511529A5 JP 2019511529 A5 JP2019511529 A5 JP 2019511529A5 JP 2018553368 A JP2018553368 A JP 2018553368A JP 2018553368 A JP2018553368 A JP 2018553368A JP 2019511529 A5 JP2019511529 A5 JP 2019511529A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- oxo
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112585A JP7278331B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321307P | 2016-04-12 | 2016-04-12 | |
| US62/321,307 | 2016-04-12 | ||
| PCT/US2017/026099 WO2017180385A1 (en) | 2016-04-12 | 2017-04-05 | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112585A Division JP7278331B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511529A JP2019511529A (ja) | 2019-04-25 |
| JP2019511529A5 true JP2019511529A5 (enExample) | 2020-05-14 |
| JP6911048B2 JP6911048B2 (ja) | 2021-07-28 |
Family
ID=58548918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553368A Expired - Fee Related JP6911048B2 (ja) | 2016-04-12 | 2017-04-05 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
| JP2021112585A Active JP7278331B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112585A Active JP7278331B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11564929B2 (enExample) |
| EP (1) | EP3442528B1 (enExample) |
| JP (2) | JP6911048B2 (enExample) |
| KR (1) | KR102418766B1 (enExample) |
| CN (1) | CN109310685B (enExample) |
| AU (1) | AU2017249988C1 (enExample) |
| CA (1) | CA3020918A1 (enExample) |
| ES (1) | ES2898952T3 (enExample) |
| MX (1) | MX380780B (enExample) |
| RU (1) | RU2754452C2 (enExample) |
| WO (1) | WO2017180385A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| KR102418765B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| KR102418766B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| EP4274662A4 (en) * | 2021-01-08 | 2024-11-27 | Lantern Pharma Inc. | Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199901343T2 (xx) | 1996-12-23 | 1999-09-21 | Elan Pharmaceuticals, Inc. | Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| WO2000020576A2 (en) | 1998-10-02 | 2000-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health | Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007004743A1 (en) | 2005-07-05 | 2007-01-11 | Fujifilm Corporation | Copolymer and polymerizable composition |
| JP4822751B2 (ja) | 2005-07-05 | 2011-11-24 | 富士フイルム株式会社 | 共重合体およびその製造方法 |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| SG10201508035TA (en) | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| CN101778826B (zh) | 2007-08-14 | 2012-10-31 | 伊莱利利公司 | 作为γ分泌酶抑制剂的氮杂*衍生物 |
| MA33076B1 (fr) | 2008-01-11 | 2012-03-01 | Hoffmann La Roche | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| EP2470054B1 (de) * | 2009-08-26 | 2013-12-04 | FrXsh AG | Vorrichtung und verfahren zum mischen von mischgut |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| JP5737903B2 (ja) | 2010-10-26 | 2015-06-17 | 三菱重工業株式会社 | 航空機用配管支持構造 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2014193898A1 (en) | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| US9827309B2 (en) | 2013-08-20 | 2017-11-28 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| US20160176962A1 (en) | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
| EP3280795B1 (en) | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| EP3662909A1 (en) | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| KR102418766B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 |
| KR102418765B1 (ko) * | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| US20190209581A1 (en) | 2016-08-31 | 2019-07-11 | Eli Lilly And Company | Dosage regimen for treatment of solid tumors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
-
2017
- 2017-04-05 KR KR1020187032282A patent/KR102418766B1/ko not_active Expired - Fee Related
- 2017-04-05 AU AU2017249988A patent/AU2017249988C1/en active Active
- 2017-04-05 MX MX2018012456A patent/MX380780B/es unknown
- 2017-04-05 US US16/093,117 patent/US11564929B2/en active Active
- 2017-04-05 WO PCT/US2017/026099 patent/WO2017180385A1/en not_active Ceased
- 2017-04-05 RU RU2018138626A patent/RU2754452C2/ru active
- 2017-04-05 JP JP2018553368A patent/JP6911048B2/ja not_active Expired - Fee Related
- 2017-04-05 ES ES17717989T patent/ES2898952T3/es active Active
- 2017-04-05 EP EP17717989.2A patent/EP3442528B1/en active Active
- 2017-04-05 CA CA3020918A patent/CA3020918A1/en active Pending
- 2017-04-05 CN CN201780036176.4A patent/CN109310685B/zh active Active
-
2021
- 2021-07-07 JP JP2021112585A patent/JP7278331B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511526A5 (enExample) | ||
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP2014132009A5 (enExample) | ||
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| JP2019517549A5 (enExample) | ||
| JP2012500180A5 (enExample) | ||
| IL263110B (en) | Combined treatment of notch and pd-1 or pd-l1 inhibitors | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2013543879A (ja) | 急性骨髄性白血病を治療するための単独またはシタラビンとの組合せにおけるボラセルチブ | |
| JP2019516733A5 (enExample) | ||
| JP2002508397A5 (enExample) | ||
| JP2014509657A5 (enExample) | ||
| JP6911048B2 (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| WO2011123691A1 (en) | Perifosine and capecitabine as a combined treatment for cancer | |
| TWI468161B (zh) | 組合藥劑之醫藥產品、試劑及用途 | |
| CN103491952A (zh) | 用于治疗癌症的新颖联合疗法 | |
| JP2003533485A5 (enExample) | ||
| RU2600793C2 (ru) | Новый режим приема n-гидрокси-4-{2-[3-(n, n-диметиламинометил)бензофуран-2-илкарбониламино]этокси}бензамида | |
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| CN110013478A (zh) | 用于抗肿瘤试剂施用的方法 | |
| JP2014512355A5 (enExample) | ||
| JP2011520846A (ja) | 多発性骨髄腫の治療 | |
| JP2023522415A5 (enExample) | ||
| JP2007520522A (ja) | （ａ）ＤＮＡトポイソメラーゼ阻害剤および（ｂ）ＩＡＰ阻害剤の組み合わせ剤 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites |